Fu Gui
Overview
Explore the profile of Fu Gui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li L, Wang Y, Wang Y, Li X, Deng Q, Gao F, et al.
Acta Pharm Sin B
. 2025 Mar;
15(1):409-423.
PMID: 40041920
Homo- or heterodimeric compounds that affect dimeric protein function through interaction between monomeric moieties and protein subunits can serve as valuable sources of potent and selective drug candidates. Here, we...
2.
Gui F, Jiang B, Jiang J, He Z, Tsujino T, Takai T, et al.
bioRxiv
. 2024 Jul;
PMID: 39026842
Current treatments for advanced prostate cancer (PCa) primarily target the androgen receptor (AR) pathway. However, the emergence of castration-resistant prostate cancer (CRPC) and resistance to AR pathway inhibitors (APSIs) remains...
3.
Xiong J, Xu J, Zhou M, Liu J, Wang Q, Yin X, et al.
J Cataract Refract Surg
. 2024 Feb;
50(6):565-571.
PMID: 38350161
Purpose: To explore the influence of preoperative factors, including varying pupil sizes and refractive attributes, on postoperative glare disability in patients undergoing implantable collamer lens (ICL) implantation. Setting: Second Affiliated...
4.
Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, et al.
Nat Commun
. 2023 Jan;
14(1):252.
PMID: 36650183
Prostate cancer harboring BRCA1/2 mutations are often exceptionally sensitive to PARP inhibitors. However, genomic alterations in other DNA damage response genes have not been consistently predictive of clinical response to...
5.
Gui F, Yu X, Wu Y, Wu C, Zhang Y
Evid Based Complement Alternat Med
. 2022 Oct;
2022:2166605.
PMID: 36248425
Objective: To explore the role of LncHOTAIR in apoptosis and autophagy in lymphoma. Methods: The interaction between LncHOTAIR and miR-6511b-5p, as well as between miR-6511b-5p and ATG7, was verified by...
6.
Liu Q, Zhu A, Gao W, Gui F, Zou Y, Zhou X, et al.
Oncol Lett
. 2022 Oct;
24(4):377.
PMID: 36238848
The present study aimed to clarify the role of microRNA (miR)-5590-3p in the progression of renal cell carcinoma (RCC) and investigate the underlying mechanisms. The expression levels of miR-5590-3p, Rho-associated...
7.
Zhang C, Li M, Wang Y, Li X, Zong Y, Long S, et al.
Nat Metab
. 2022 Oct;
4(10):1369-1401.
PMID: 36217034
The activity of 5'-adenosine monophosphate-activated protein kinase (AMPK) is inversely correlated with the cellular availability of glucose. When glucose levels are low, the glycolytic enzyme aldolase is not bound to...
8.
Xu X, Lan X, Fu S, Zhang Q, Gui F, Jin Q, et al.
Biochem Biophys Res Commun
. 2022 Jun;
617(Pt 2):69-76.
PMID: 35691117
Diabetic retinopathy (DR) is a key reason for legal blindness worldwide. Currently, it is urgently necessary to determine the etiology and pathological molecular mechanism of DR to search for resultful...
9.
Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, et al.
Sci Adv
. 2022 Feb;
8(7):eabl9794.
PMID: 35179959
Current targeted cancer therapies are largely guided by mutations of a single gene, which overlooks concurrent genomic alterations. Here, we show that , , and , three closely located genes...
10.
Gao W, Zhang S, Guorong L, Liu Q, Zhu A, Gui F, et al.
Cell Cycle
. 2022 Jan;
21(4):340-351.
PMID: 34974812
Drug resistance is a significant challenge in the present treatment regimens of renal cell carcinoma (RCC). Our previous study confirmed that nc886 functions as an oncogene in RCC. Nevertheless, the...